In this podcast, Dominick J. Angiolillo, MD, PhD, provides insight into a new analysis of the TWILIGHT trial that he and his colleagues performed among high-risk patients with diabetes. It was a topic he discussed during ACC.20/WCC Virtual, when he presented the session, “Ticagrelor With and Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: Insights From the TWILIGHT Trial.” For more, click here: www.consultant360.com/cardiology

Nolan Williams, MD, on the SAINT Depression Trial by Consultant360

In this podcast, Mark Pimentel, MD, talks about the American College of Gastroenterology's new clinical guideline on small intestinal bacterial overgrowth (SIBO), how the guideline attempts to clear up the controversies around diagnosis and treatment of SIBO, and more. More at: www.consultant360.com/gastroenterology

While researchers originally explored sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide (GLP)-1 receptor agonists for their impact on blood glucose, the two classes of agents were unexpectedly found to have cardiovascular benefits. In this podcast, Ralph Brindis, MD, MPH, interviews Laurence Sperling, MD, about implementing SGLT2 inhibitors and GLP-1 receptor agonists into the treatment of patients with cardiovascular disease and diabetes. For more, click here: www.consultant360.com/cardiology

In this podcast, George Karpouzas, MD, talks about his research on highly sensitive cardiac troponin-I and IgA antibodies against β-2 glycoprotein 1 in the setting of coronary atherosclerosis among patients with rheumatoid arthritis. More at: www.consultant360.com/rheumatology

In this podcast, George Karpouzas, MD, discusses his research that evaluated whether β-2 glycoprotein 1 IgA antibodies can predict coronary plaque burden and progression, and whether the antibodies moderate the effect of inflammation on atherosclerosis among patients with rheumatoid arthritis. More at: www.consultan360.com/rheumatology

In this podcast, George Karpouzas, MD, talks about his study that evaluated whether biologic disease-modifying antirheumatic drugs reduce long-term risk of cardiovascular events in patients with rheumatoid arthritis, as well as their mechanism of action. More at: www.consultant360.com/rheumatology.

In this podcast, George Karpouzas, MD, talks about his study that evaluated the impact of inflammation, cardiac risk factors, duration of medication exposure, and their interactions on coronary plaque progression among patients with rheumatoid arthritis. More at: www.consultant360.com/rheumatology.

In this podcast, J. Antonio Aviña-Zubieta, MD, MSc, PhD, from the University of British Columbia, discusses his research on the overall risk and temporal trends of venous thromboembolism, deep vein thrombosis, and pulmonary embolism in patients with gout, as well as how rheumatologists can approach management. More at: www.consultant360.com/rheumatology

In this podcast, Dr Eiras discusses his experience with treating patients in New York City amid the COVID-19 pandemic, and how the pandemic has changed his practice. For more, visit www.consultant360.com/infectious-diseases.